Spritam Tablet, For Suspension
Product Images NDC 43485-102

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Spritam (NDC 43485-102). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aprecia Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Recommended Dosage Adjustment Formula (Spritam 01)

A pharmacokinetic equation panel showing the formula to calculate creatinine clearance (CLcr). The formula includes variables for age, weight, serum creatinine levels, and a multiplication factor for female patients, representing renal function estimation required for dosing considerations.*

FDA Label Image

Recommended Dosage Adjustment Formula (Spritam 02)

A mathematical formula diagram depicting the calculation of creatinine clearance (CLcr) in mL/min and mL/min/1.73 m². It shows the formula multiplying the clearance adjusted to body surface area (BSA) in m² by 1.73 to determine CLcr in mL/min.*

FDA Label Image

Imprint Marking (Spritam 03)

Spritam 1000 mg levetiracetam tablet for suspension bottle with a white and blue label. The label displays dosage strength, administration route (oral), and the labeler Aprecia Pharmaceuticals, LLC. The bottle has a white cap and contains 30 tablets for suspension.*

FDA Label Image

Imprint Marking (Spritam 04)

Drug Facts text panel for Spritam (levetiracetam) tablets for suspension. The panel includes detailed information about the drug's uses, warnings, directions, and inactive ingredients, along with storage instructions and other consumer guidance.*

FDA Label Image

Imprint Marking (Spritam 05)

Spritam levetiracetam oral tablet for suspension packaging label showing 250 mg strength, manufactured by Aprecia Pharmaceuticals, LLC. The label displays product information including the proprietary and generic names, dosage form, and strength prominently on the front face of the box.*

FDA Label Image

Imprint Marking (Spritam 06)

Spritam 1000 mg levetiracetam oral tablet for suspension packaging label by Aprecia Pharmaceuticals, LLC. The label shows the 1000 mg strength of levetiracetam formulated as a tablet intended for oral suspension.*

FDA Label Image

Chemical Structure (Spritam 07)

Chemical structure diagram of levetiracetam, the active ingredient in Spritam, showing its molecular arrangement including the pyrrolidone ring, amide group, and ethyl side chain.*

FDA Label Image

Figure 1 (Spritam 08)

Bar chart showing the percentage of patients experiencing an event under three conditions: Placebo (7.4% of 95 patients), Levetiracetam 1000 mg/day (37.1% of 97 patients), and Levetiracetam 3000 mg/day (39.6% of 101 patients). Statistical significance is indicated for levetiracetam groups compared to placebo.*

FDA Label Image

Figure 2 (Spritam 09)

A bar chart showing the percentage of patients for three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The vertical axis represents the percentage of patients, ranging from 0% to 45%. Each bar includes a sample size (N) and an asterisk indicating statistical significance.*

FDA Label Image

Figure 3 (Spritam 10)

A bar chart comparing the percentage of patients between two groups: Placebo (104 patients) with 14.4% and Levetiracetam 3000 mg/day (180 patients) with 39.4%. The y-axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

Figure 4 (Spritam 11)

Bar chart comparing the percentage of patients between Placebo (N=97) and Levetiracetam (N=101) groups. The Levetiracetam group shows a higher percentage of patients around 44.6%, while the Placebo group shows approximately 19.6%. The vertical axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

Figure 5 (Spritam 12)

A bar graph comparing the percentage of patients for placebo (N=84) and levetiracetam (N=79). The placebo group shows 45.2% of patients, while the levetiracetam group shows 72.2%, indicating a higher percentage for levetiracetam.*

FDA Label Image

Imprint Marking (Spritam 13)

Spritam levetiracetam 1000 mg tablet for suspension carton. The packaging features a white and blue design with a large '1000mg' label, the product name Spritam, and dosage form indicated. The labeler is Aprecia Pharmaceuticals, LLC. The quantity and precise NDC number are not visible.*

FDA Label Image

Imprint Marking (Spritam 14)

Chemical structure of levetiracetam, the active ingredient in Spritam, shown as a molecular diagram with labeled atoms and bonds.*

FDA Label Image

Imprint Marking (Spritam 15)

Spritam 1000 mg levetiracetam tablet for suspension carton from Aprecia Pharmaceuticals, LLC. The packaging is for an oral prescription drug suspension dosage form, prominently displaying the product name and active ingredient strength on a white background with blue and orange accents.*

FDA Label Image

Imprint Marking (Spritam 16)

Spritam levetiracetam 1000 mg oral tablet for suspension packaging label from Aprecia Pharmaceuticals, LLC. The label displays the brand name Spritam prominently with the active ingredient levetiracetam and dosage strength of 1000 mg per tablet for suspension.*

FDA Label Image

Imprint Marking (Spritam 17)

Spritam 250 mg tablet for oral suspension packaging label by Aprecia Pharmaceuticals, LLC. The label shows the product name, levetiracetam as the active ingredient, and indicates 250 mg per tablet strength. The package contains 60 tablets (6 tablets per blister card x 10 cards). Instructions with illustrations for tablet use are included, along with dosage recommendations and storage information. The label also features barcodes and manufacturer details.*

FDA Label Image

Imprint Marking (Spritam 18)

The image shows a flattened packaging label for Spritam 500 mg tablets for oral suspension by Aprecia Pharmaceuticals, LLC. The label features the Spritam logo, strength (500 mg per tablet), and dosage form. It indicates a 60-tablet supply (6 tablets per blister card, 10 cards per box). There are instructions for use and handling, and storage information is partly visible.*

FDA Label Image

Imprint Marking (Spritam 19)

Spritam 750 mg tablet for oral suspension packaging label showing the front and sides of the carton. The labeler is Aprecia Pharmaceuticals, LLC. Package contains 60 tablets (6 tablets per blister card x 10 cards). Instructions illustrate how to peel the blister foil and take the tablet with a sip of liquid. The label states each tablet contains levetiracetam 750 mg and directions to dispense a Medication Guide with each patient.*

FDA Label Image

Imprint Marking (Spritam 20)

Spritam 1000 mg tablets for oral suspension label for a 60-tablet package (6 tablets per blister card x 10 cards) by Aprecia Pharmaceuticals, LLC. The label includes usage instructions, storage information, and barcode. The product contains levetiracetam 1000 mg per tablet and is indicated for oral suspension use. The label states to dispense accompanying medication guidance to each patient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.